4 results
Primary: To assess 6 month PFS rate of Nivolumab in combination with EGF816 in EGFR mutated NSCLC patients and of Nivolumab in combination with INC280 in patients with cMET positive NSCLC patientsSecondary: 1: To assess clinical activity of…
Primary objective: Determine for different control algorithms whether the algorithm is effective in providing the patient with the required support and bringing about the desired changes in the walking patternSecondary Objective(s): - Determine…
Primary objectives:1. What is the effect of walking on a treadmill compared to walking in a patient-in-charge mode on kinematics in healthy subjects?2. What is the effect of walking on a treadmill compared to walking in a patient-in-charge mode on…
Phase I partPrimary:* Determine the maximum tolerated dose (MTD) or the recommended phase II dose (RP2D).Secondary:* Safety and tolerability, * ORR, duration of response (DOR), disease control rate (DCR), progression free survival (PFS) and time to…